CNS Pharmaceuticals Financials
This page shows CNS Pharmaceuticals (CNSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CNS Pharmaceuticals operates as a financing-supported development business, with research spending and cash needs exceeding internally generated funds.
In FY2025, operating cash flow of-$13.8M nearly matched net loss of-$15.9M , indicating the reported loss largely reflects cash-consuming operations rather than mainly non-cash charges. Free cash flow of-$13.8M was almost identical because capital expenditures were only$18K , so reinvestment is not the main reason cash is leaving.
R&D consumed
FY2025 financing cash flow of
Financial Health Signals
CNS Pharmaceuticals does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CNS Pharmaceuticals passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.
CNS Pharmaceuticals reported a net loss of $16K while operations used $13.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CNS Pharmaceuticals reported an operating loss of $16.0M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CNS Pharmaceuticals's EBITDA was -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.3% from the prior year.
CNS Pharmaceuticals reported -$16K in net income in fiscal year 2025. This represents a decrease of 7.6% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
CNS Pharmaceuticals recorded an outflow of $13.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 19.2% from the prior year.
CNS Pharmaceuticals held $7.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
CNS Pharmaceuticals's ROE was -0.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
CNS Pharmaceuticals invested $9.8M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.
CNS Pharmaceuticals invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 334.0% from the prior year.
Not reported for fiscal year 2025.
CNSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.2M-66.1% | $3.5M | N/A | $2.2M+88.2% | $1.2M-64.0% | $3.2M | N/A | $4.2M |
| SG&A Expenses | $1.5M+4.7% | $1.4M | N/A | $1.1M-14.9% | $1.2M+13.5% | $1.1M | N/A | $1.4M |
| Operating Income | -$2.7M+45.7% | -$5.0M | N/A | -$3.3M-35.1% | -$2.4M+44.5% | -$4.3M | N/A | -$5.6M |
| Interest Expense | $4K-34.5% | $6K | N/A | $2K-47.1% | $4K-35.6% | $6K | N/A | $2K |
| Net Income | -$2.6M+47.6% | -$4.9M | N/A | -$3.2M-35.5% | -$2.4M+44.8% | -$4.3M | N/A | -$5.6M |
| EPS (Diluted) | -$0.38 | -$7.30+28.1% | -$10.15-76.2% | -$5.76 | -$6.42 | -$18.93+49.3% | -$37.33 | -$153.20 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
CNSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.9M+371.5% | $4.7M-46.0% | $8.6M-27.4% | $11.9M-18.2% | $14.5M+5.5% | $13.7M+58.0% | $8.7M+17.4% | $7.4M |
| Current Assets | $21.9M+437.5% | $4.1M-49.7% | $8.1M-28.9% | $11.4M-19.4% | $14.1M+3.0% | $13.7M+58.5% | $8.7M+17.2% | $7.4M |
| Cash & Equivalents | $20.0M+577.3% | $3.0M-59.0% | $7.2M-27.0% | $9.9M-18.7% | $12.1M-7.0% | $13.0M+101.9% | $6.5M-7.3% | $7.0M |
| Total Liabilities | $3.7M-18.4% | $4.6M+11.8% | $4.1M+109.3% | $2.0M+41.7% | $1.4M-50.2% | $2.8M+10.1% | $2.5M-37.8% | $4.1M |
| Current Liabilities | $3.7M-18.4% | $4.6M+11.8% | $4.1M+109.3% | $2.0M+41.7% | $1.4M-50.2% | $2.8M+10.1% | $2.5M-37.8% | $4.1M |
| Total Equity | $18.2M+25533.8% | $71K-98.4% | $4.5M-54.4% | $9.9M-24.5% | $13.1M+19.6% | $11.0M+77.6% | $6.2M+84.3% | $3.4M |
| Retained Earnings | -$107.8M-2.5% | -$105.2M-4.9% | -$100.3M-6.3% | -$94.3M-3.5% | -$91.1M-2.7% | -$88.7M-5.1% | -$84.4M-3.9% | -$81.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CNSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M+23.9% | -$4.6M-52.3% | -$3.1M-40.4% | -$2.2M+59.3% | -$5.3M-64.8% | -$3.2M+40.7% | -$5.5M+19.5% | -$6.8M |
| Capital Expenditures | $4K-38.2% | $6K | N/A | N/A | $0 | $0-100.0% | $4K | N/A |
| Free Cash Flow | -$3.5M+23.9% | -$4.7M | N/A | N/A | -$5.3M-64.8% | -$3.2M+40.8% | -$5.5M | N/A |
| Investing Cash Flow | -$4K+38.2% | -$6K | N/A | N/A | $0 | $0+100.0% | -$4K | N/A |
| Financing Cash Flow | $20.6M+4985.1% | $405K-0.5% | $407K+542.5% | -$92K-102.1% | $4.4M-55.0% | $9.8M+98.0% | $5.0M-59.6% | $12.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CNSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -14.2%+6939.3pp | -6953.5% | N/A | -32.5%-14.4pp | -18.1%+21.1pp | -39.2% | N/A | -167.2% |
| Return on Assets | -11.8%+94.3pp | -106.1% | N/A | -27.1%-10.7pp | -16.4%+14.9pp | -31.3% | N/A | -75.7% |
| Current Ratio | 5.86+5.0x | 0.89-1.1x | 1.98-3.8x | 5.81-4.4x | 10.22+5.3x | 4.94+1.5x | 3.43+1.6x | 1.82 |
| Debt-to-Equity | 0.21-64.3x | 64.54+63.6x | 0.91+0.7x | 0.20+0.1x | 0.11-0.1x | 0.25-0.2x | 0.41-0.8x | 1.21 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where CNS Pharmaceuticals Ranks
Frequently Asked Questions
Is CNS Pharmaceuticals profitable?
No, CNS Pharmaceuticals (CNSP) reported a net income of -$16K in fiscal year 2025.
What is CNS Pharmaceuticals's EBITDA?
CNS Pharmaceuticals (CNSP) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CNS Pharmaceuticals's return on equity (ROE)?
CNS Pharmaceuticals (CNSP) has a return on equity of -0.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CNS Pharmaceuticals's free cash flow?
CNS Pharmaceuticals (CNSP) recorded an outflow of $13.8M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CNS Pharmaceuticals's operating cash flow?
CNS Pharmaceuticals (CNSP) recorded an outflow of $13.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CNS Pharmaceuticals's total assets?
CNS Pharmaceuticals (CNSP) had $8.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CNS Pharmaceuticals's capital expenditures?
CNS Pharmaceuticals (CNSP) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CNS Pharmaceuticals spend on research and development?
CNS Pharmaceuticals (CNSP) invested $9.8M in research and development during fiscal year 2025.
What is CNS Pharmaceuticals's current ratio?
CNS Pharmaceuticals (CNSP) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.
What is CNS Pharmaceuticals's debt-to-equity ratio?
CNS Pharmaceuticals (CNSP) had a debt-to-equity ratio of 0.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CNS Pharmaceuticals's return on assets (ROA)?
CNS Pharmaceuticals (CNSP) had a return on assets of -0.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does CNS Pharmaceuticals's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CNS Pharmaceuticals (CNSP) held $7.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is CNS Pharmaceuticals's Piotroski F-Score?
CNS Pharmaceuticals (CNSP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CNS Pharmaceuticals's earnings high quality?
CNS Pharmaceuticals (CNSP) reported a net loss of $16K while operations used $13.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CNS Pharmaceuticals cover its interest payments?
CNS Pharmaceuticals (CNSP) reported an operating loss of $16.0M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.